Antimalarial preclinical drug development: A single oral dose of a 5-carbon-linked trioxane dimer plus mefloquine cures malaria-infected mice

Deuk Kyu Moon, Vandana Singhal, Nirbhay Kumar, Theresa A. Shapiro, Gary H. Posner

Research output: Contribution to journalArticlepeer-review

Abstract

Three new 5-carbon-linked trioxane dimer carboxylate esters have been prepared from the natural trioxane, artemisinin, in only three steps and 40-50% overall yields. Each one of these new chemical entities is at least as efficacious as the clinically used trioxane antimalarial drug artemether when combined with mefloquine hydrochloride in a low single oral dose cure.

Original languageEnglish (US)
Pages (from-to)76-81
Number of pages6
JournalDrug Development Research
Volume71
Issue number1
DOIs
StatePublished - Feb 1 2010

Keywords

  • Antimalarial chemotherapy
  • Artemisinin combination therapy (ACT)
  • Single oral dose ACT cure
  • Trioxane dimers

ASJC Scopus subject areas

  • Drug Discovery

Fingerprint Dive into the research topics of 'Antimalarial preclinical drug development: A single oral dose of a 5-carbon-linked trioxane dimer plus mefloquine cures malaria-infected mice'. Together they form a unique fingerprint.

Cite this